Genmab Gets EC Grants Marketing Authorization for Tivdak as Cervical Cancer Treatment

 TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

• TIVDAK® is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or after systemic therapy
• In the global Phase 3 innovaTV 301 clinical trial TIVDAK demonstrated superior overall survival compared to chemotherapy
• TIVDAK is approved for the treatment of recurrent or metastatic cervical cancer in the European Union, United States and Japan

https://www.morningstar.com/news/business-wire/20250331621626/tivdak-tisotumab-vedotin-approved-by-european-commission-for-previously-treated-recurrent-or-metastatic-cervical-cancer